Literature DB >> 25725779

Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia.

Takahiro Moriyama1, Akira Matsunaga, Osamu Nagata, Kei Enohata, Tomomi Kamikawaji, Erika Uchino, Yuichi Kanmura.   

Abstract

BACKGROUND: Rocuronium bromide (Rb) is a rapid onset, intermediate-acting neuromuscular blocking agent that is suitable for continuous administration. The appropriate rate of rocuronium administration is, however, difficult to determine due to large interindividual differences in sensitivity to rocuronium. The aim of this study was to clarify whether the simulated rocuronium concentration at the time of recovery to %T1 > 0 % after the initial administration of rocuronium is a good indicator of optimal effect-site concentrations during continuous rocuronium administration.
METHODS: Twenty-one patients were anesthetized with propofol. After induction, Rb 0.6 mg/kg was administered intravenously, and nerve stimulation using the single stimulation mode was conducted every 15 s. When %T1 recovered to >0 % after the initial administration of Rb, the effect-site concentration of rocuronium, calculated by pharmacokinetic simulation with Wierda's set of parameters, was recorded and defined as the recovery concentration (Rb r.c.). The administration rate of rocuronium was adjusted to maintain the Rb r.c. during surgery. Rb administration was discontinued just before the end of surgery, and the recovery time until %T1 > 25 % was recorded. Plasma Rb concentrations were measured at 1 and 3 h after the initiation of continuous Rb administration. RESULT: The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively. The %T1 did not increase above 10 % in any of the patients during continuous administration of Rb, and the recovery period to %T1 > 25 % ranged from 9 to 29 min. The effect-site concentrations of Rb calculated with Wierda's parameters significantly correlated with plasma concentrations (P < 0.01) at both 1 and 3 h after the initial administration of Rb.
CONCLUSION: The results suggest that our method may be one of the most reliable protocols for the continuous administration of Rb described to date for maintaining suitable muscle relaxation during surgery without excessively prolonged effects.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25725779     DOI: 10.1007/s00540-015-1991-2

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  24 in total

1.  Postoperative residual block after intermediate-acting neuromuscular blocking drugs.

Authors:  A H Hayes; R K Mirakhur; D S Breslin; J E Reid; K C McCourt
Journal:  Anaesthesia       Date:  2001-04       Impact factor: 6.955

2.  Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action.

Authors:  Bertrand Debaene; Benoît Plaud; Marie-Pierre Dilly; François Donati
Journal:  Anesthesiology       Date:  2003-05       Impact factor: 7.892

3.  The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients.

Authors:  Yigal Leykin; Tommaso Pellis; Mariella Lucca; Giacomina Lomangino; Bernardo Marzano; Antonino Gullo
Journal:  Anesth Analg       Date:  2004-10       Impact factor: 5.108

4.  Postoperative residual paralysis in outpatients versus inpatients.

Authors:  Guy Cammu; Jan De Witte; Jan De Veylder; Geert Byttebier; Dirk Vandeput; Luc Foubert; Geert Vandenbroucke; Thierry Deloof
Journal:  Anesth Analg       Date:  2006-02       Impact factor: 5.108

5.  Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision.

Authors:  T Fuchs-Buder; C Claudius; L T Skovgaard; L I Eriksson; R K Mirakhur; J Viby-Mogensen
Journal:  Acta Anaesthesiol Scand       Date:  2007-08       Impact factor: 2.105

6.  The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.

Authors:  J M Wierda; U W Kleef; L M Lambalk; W D Kloppenburg; S Agoston
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

7.  Geographic regional differences in rocuronium bromide dose-response relation and time course of action: an overlooked factor in determining recommended dosage.

Authors:  Ashraf A Dahaba; Seth I Perelman; David M Moskowitz; Henry L Bennett; Aryeh Shander; Zhaoyang Xiao; Lin Huang; Gang An; Helmar Bornemann; Georg Wilfinger; Barbara Hager; Peter H Rehak; Werner F List; Helfried Metzler
Journal:  Anesthesiology       Date:  2006-05       Impact factor: 7.892

8.  [Randomized, multicenter study of interaction between Org 9426 (rocuronium bromide) and anesthetic agents in Japanese population].

Authors:  Yoshifumi Kotake; Junzo Takeda; Makoto Ozaki; Shigeru Saeki; Tetsutaro Otagiri; Shuya Kiyama; Ryogo Uchimoto; Yasuhide Iwao
Journal:  Masui       Date:  2006-07

9.  Should dosing of rocuronium in obese patients be based on ideal or corrected body weight?

Authors:  Christian S Meyhoff; Jørgen Lund; Morten T Jenstrup; Casper Claudius; Anne M Sørensen; Jørgen Viby-Mogensen; Lars S Rasmussen
Journal:  Anesth Analg       Date:  2009-09       Impact factor: 5.108

10.  Analysis of rocuronium in human plasma by liquid chromatography-tandem mass spectrometry with application in clinical pharmacokinetics.

Authors:  Natália Valadares de Moraes; Gabriela Rocha Lauretti; Gabriela Campos de Oliveira Filgueira; Bruno Carvalho Portes Lopes; Vera Lucia Lanchote
Journal:  J Pharm Biomed Anal       Date:  2013-12-07       Impact factor: 3.935

View more
  1 in total

1.  Rocuronium bromide: clinical application of single-dose pharmacokinetic models to continuous infusion.

Authors:  Yutaka Oda
Journal:  J Anesth       Date:  2017-08-21       Impact factor: 2.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.